Astute Medical Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 46

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $90M

Astute Medical General Information

Description

Developer of biomarkers intended for acute medical conditions and diseases. The company's biomarkers can serve as the basis for novel diagnostic tests for abdominal pain, cerebrovascular injury, acute coronary syndromes, kidney injury and sepsis, helping clinicians improve patient outcomes.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 3550 General Atomics Court Building
  • 02/620
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Acquirer
Vertical(s)
Corporate Office
  • 3550 General Atomics Court Building
  • 02/620
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Astute Medical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 04-Apr-2018 $90M Completed Generating Revenue
8. Later Stage VC (Series F) 14-Dec-2016 Completed Generating Revenue
7. Later Stage VC (Series E) 14-Oct-2015 Completed Generating Revenue
6. Debt - General 09-Oct-2014 Completed Generating Revenue
5. Later Stage VC (Series D) 29-Jul-2014 Completed Generating Revenue
4. Debt - General 21-Dec-2012 Completed Generating Revenue
3. Later Stage VC (Series C) 07-Jun-2012 Completed Generating Revenue
2. Early Stage VC (Series B) 08-Mar-2011 $39.7M $46M Completed Generating Revenue
1. Early Stage VC (Series A) 01-May-2008 $6.37M $6.37M Completed Product Development
To view Astute Medical’s complete valuation and funding history, request access »

Astute Medical Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series F
Series E
Series D
Series C
Series B 12,264,196 $0.000100 8% $3.23 $3.23 1x $3.23 22.01%
Series A 2,068,182 $0.000100 8% $3.08 $3.08 1x $3.08 3.71%
To view Astute Medical’s complete cap table history, request access »

Astute Medical Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biomarkers intended for acute medical conditions and diseases. The company's biomarkers can serve as the ba
Biotechnology
San Diego, CA
46 As of 2020

Frederick, MD
 

Cincinnati, OH
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Astute Medical Competitors (6)

One of Astute Medical’s 6 competitors is Akonni Biosystems, a Venture Capital-Backed company based in Frederick, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Akonni Biosystems Venture Capital-Backed Frederick, MD
Meridian Bioscience Private Equity-Backed Cincinnati, OH
Decipher Urologic Cancers Formerly VC-backed San Diego, CA
Genomind Venture Capital-Backed King of Prussia, PA
Boston Scientific Corporation Marlborough, MA
To view Astute Medical’s complete competitors history, request access »

Astute Medical Patents

Astute Medical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023229375-A1 Methods and compositions for assessing and treating persistent acute kidney injury based on c-c motif chemokine ligand 14 measurement Pending 03-Mar-2022
EP-4487114-A1 Methods and compositions for assessing and treating persistent acute kidney injury based on c-c motif chemokine ligand 14 measurement Pending 03-Mar-2022
EP-4487114-A4 Methods and compositions for assessing and treating persistent acute kidney injury based on c-c motif chemokine ligand 14 measurement Pending 03-Mar-2022
WO-2023168299-A1 Methods and compositions for assessing and treating persistent acute kidney injury based on c-c motif chemokine ligand 14 measurement Inactive 03-Mar-2022
AU-2021381364-A1 Methods and compositions for treatment of renal injury and renal failure Pending 18-Nov-2020 A61K35/14
To view Astute Medical’s complete patent history, request access »

Astute Medical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Astute Medical Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bio-Techne Corporation Minority
CRG Lender/Debt Provider Minority
De Novo Ventures Venture Capital Minority
Delphi Ventures (California) Venture Capital Minority
Domain Associates Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Astute Medical FAQs

  • When was Astute Medical founded?

    Astute Medical was founded in 2007.

  • Where is Astute Medical headquartered?

    Astute Medical is headquartered in San Diego, CA.

  • What is the size of Astute Medical?

    Astute Medical has 46 total employees.

  • What industry is Astute Medical in?

    Astute Medical’s primary industry is Biotechnology.

  • Is Astute Medical a private or public company?

    Astute Medical is a Private company.

  • What is the current valuation of Astute Medical?

    The current valuation of Astute Medical is .

  • What is Astute Medical’s current revenue?

    The current revenue for Astute Medical is .

  • How much funding has Astute Medical raised over time?

    Astute Medical has raised $200M.

  • Who are Astute Medical’s investors?

    Bio-Techne, CRG, De Novo Ventures, Delphi Ventures (California), and Domain Associates are 5 of 10 investors who have invested in Astute Medical.

  • Who are Astute Medical’s competitors?

    Akonni Biosystems, Meridian Bioscience, Decipher Urologic Cancers, Genomind, and Boston Scientific are some of the 6 competitors of Astute Medical.

  • When was Astute Medical acquired?

    Astute Medical was acquired on 04-Apr-2018.

  • Who acquired Astute Medical?

    Astute Medical was acquired by BioMérieux.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process